Advertisement

Topics

Study of a DNA Immunotherapy to Treat Melanoma

2014-07-24 14:01:05 | BioPortfolio

Summary

The study is an investigation of a novel immunotherapy, SCIB1, for the treatment of melanoma. SCIB1 is a solution of plasmid DNA molecules which will express a modified antibody in human cells. The antibody modifications are designed to stimulate the patient's immune T cells to have a strong and specific reaction against melanoma cells which should then be eliminated. SCIB1 is injected into muscle using a device which simultaneously delivers an electrical impulse to enhance the transfer of SCIB1 into muscle cells. The trial will assess the safety and tolerability of SCIB1, the safety and performance of the injection device and the immunological effects of SCIB1. This is the first study of SCIB1 in humans and the trial has two parts, in the first part the dose will be escalated to determine a safe and tolerable level up to a maximum of 4 mg per dose. In the second part patients will receive the dose determined in the first part. All patients will receive 5 injections of SCIB1 over 5.5 months. Patients will have stage III or IV melanoma, be HLA type A2 and have a life expectancy of at least three months. The study will be conducted at major cancer centres in the UK only and is expected to last for two years. Patients will be followed up for five years after they have completed the trial.

Study Design

Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Malignant Melanoma

Intervention

SCIB1

Location

Christie Hospital
Manchester
United Kingdom
M20 4BX

Status

Recruiting

Source

Scancell Ltd

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:01:05-0400

Clinical Trials [1448 Associated Clinical Trials listed on BioPortfolio]

Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy

Malignant melanoma have been reported to be characterized with high gp100 expression. Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the ...

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

The purpose of this research study is to find out whether JX-594 is safe and effective for treating surgically unresectable malignant melanoma.

The Identification of Novel Prognostic Markers in Melanoma

The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until comple...

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA ...

PubMed Articles [2440 Associated PubMed Articles listed on BioPortfolio]

Nestin Expression in Spitzoid Lesions: An Immunohistochemical Characterization With Clinical and Dermoscopic Correlations.

Spindle or epithelioid melanocytic (Spitz) nevi usually affect children or adolescents and growth in the face or the lower extremities. Histologically, they may show cytoarchitectural atypia and mitot...

MicroRNA-143-3p inhibits growth and invasiveness of melanoma cells by targeting cyclooxygenase-2 and inversely correlates with malignant melanoma progression.

Malignant melanoma is one of the most leading form of skin cancer associated with a low patient survival rate. Increasing evidence revealed that microRNAs (miRNAs) play a crucial role in the occurrenc...

Primary Malignant Melanoma in the Pineal Region: Case Report and Literature Review.

 Primary pineal malignant melanoma is a rare type of primary central nervous system melanoma with only 19 cases reported in the literature.

Ovostatin 2 knockdown significantly inhibits the growth, migration, and tumorigenicity of cutaneous malignant melanoma cells.

We previously identified ovostatin 2 (OVOS2) as a new candidate gene for cutaneous malignant melanoma (CMM) in a Chinese population. In this study, we aimed to investigate the exact role of OVOS2 in c...

Metastasis from a malignant melanoma presenting as a gall bladder polyp.

Gall bladder polyps larger than 10 mm hold an increased risk of malignancy. In this case report, a metastasis from a superficial spreading malignant melanoma level IV presented as a large gall bladder...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)

More From BioPortfolio on "Study of a DNA Immunotherapy to Treat Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Searches Linking to this Trial